Delivery Order SPE2DP20D0002-SPE2DP26F0984
Award Date 12/1/25
Potential Completion Date 12/9/25
Potential Value $330K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Parsippany, NJ 07054, USA
Solicitation Procedures
Only One Source
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded Teva Pharmaceuticals USA, Inc. a firm fixed-price delivery order valued at $165,156.93 for Adenovirus Type 4 vaccine with an ultimate completion date of September 23, 2025. The contract, issued without a set-aside designation, is being performed in Parsippany, New Jersey, where Teva maintains its U.S. headquarters. This delivery order supports the Department of Defense's immunization programs and represents part of Teva's established role as a critical...
- Teva Pharmaceuticals USA, Inc. has been awarded a $1,526,969 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to supply adenovirus type 4 vaccine. This delivery order was issued under an existing contract vehicle and will support the immunization programs of the military. Teva will deliver the vaccine products to the agency's location in Parsippany, New Jersey by December 19, 2023. As a major pharmaceutical manufacturer, Teva has extensive experience...
- The U.S. Department of Defense's Medical Supply Chain awarded a $1.32 million firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with performance scheduled for completion by December 9, 2025. This delivery order, issued without set-aside designation, represents one of over 150 awards Teva has received since 2023 under indefinite delivery contract vehicles, primarily through the Defense Logistics Agency Troop Support Medical. The vaccine will be...
- On December 1, 2025, the Defense Logistics Agency Troop Support Medical awarded a $330,313.86 firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for the supply of Adenovirus Type 4 vaccine. The contract, with an ultimate completion date of December 9, 2025, represents a delivery order issued under an indefinite delivery contract vehicle and will be performed at Teva's facility in Parsippany, New Jersey. This award carries no set-aside designation and is structured as a firm...
- Teva Pharmaceuticals USA, Inc., headquartered in Parsippany, New Jersey, was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. This firm-fixed-price contract, issued without a set-aside designation, supports the Medical Supply Chain within the Department of Defense. The delivery order represents a continuation of Teva's established role as a critical supplier of the Adenovirus Type 4...
- Teva Pharmaceuticals USA, Inc. was awarded a Firm Fixed Price Delivery Order by the Defense Logistics Agency Troop Support Medical to provide Adenovirus Type 4 vaccine in Parsippany, New Jersey. The contract has a potential value of $146,823.93 and a completion date of December 20, 2022. Teva is a foreign-owned, for-profit manufacturer that has a history of providing pharmaceutical products, including vaccines and respiratory treatments, to various federal customers such as the Department of...
- Teva Pharmaceuticals USA, Inc. has been awarded a $305,393.76 firm fixed price delivery order from the Defense Logistics Agency Troop Support Medical to provide adenovirus type 4 vaccine. Performance will take place in Parsippany, New Jersey through December 2023. This delivery order was issued against an existing contract vehicle and supports the immunization programs of the military. Teva Pharmaceuticals has a history of partnering with subcontractors and receiving contract awards to supply...
- Teva Pharmaceuticals USA, Inc. was awarded a delivery order valued at $825,784.65 for Adenovirus Type 4 vaccine by the Defense Logistics Agency's Medical Supply Chain division on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm-fixed-price delivery order with no set-aside designation, indicating Teva competed as a large business in an unrestricted solicitation. Performance will take place at Teva's facility in Parsippany, New Jersey....
- The U.S. Department of Defense's Medical Supply Chain division awarded a $1.16M firm fixed-price delivery order to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine, with an ultimate completion date of August 26, 2025. The contract, which carries no set-aside designation, will be performed at Teva's manufacturing facility in Parsippany, New Jersey. This delivery order represents a continuation of Teva's established role as a critical supplier of vaccines and pharmaceutical products to...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order valued at $825,784.65 to Teva Pharmaceuticals USA, Inc. for Adenovirus Type 4 vaccine on September 8, 2025, with an ultimate completion date of September 23, 2025. The contract is structured as a firm fixed-price delivery order with no set-aside designation, and performance will be executed at Teva's facility in Parsippany, New Jersey. This delivery order is issued under a larger indefinite delivery vehicle and...